|
1
|
Sarin SK, Kumar A, Almeida JA, et al:
Acute-on-chronic liver failure: consensus recommendations of the
Asian Pacific Association for the study of the liver (APASL).
Hepatol Int. 3:269–282. 2009. View Article : Google Scholar
|
|
2
|
Wong VW and Chan HL: Severe acute
exacerbation of chronic hepatitis B: a unique presentation of a
common disease. J Gastroenterol Hepatol. 24:1179–1186. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kamath PS and Kim WR; Advanced Liver
Disease Study Group. The model for end-stage liver disease (MELD).
Hepatology. 45:797–805. 2007. View Article : Google Scholar
|
|
4
|
Gitto S, Lorenzini S, Biselli M, Conti F,
Andreone P and Bernardi M: Allocation priority in non-urgent liver
transplantation: an overview of proposed scoring systems. Dig Liver
Dis. 41:700–706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun LJ, Yu JW, Zhao YH, Kang P and Li SC:
Influential factors of prognosis in lamivudine treatment for
patients with acute-on-chronic hepatitis B liver failure. J
Gastroenterol Hepatol. 25:583–590. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun QF, Ding JG, Xu DZ, et al: Prediction
of the prognosis of patients with acute-on-chronic hepatitis B
liver failure using the model for end-stage liver disease scoring
system and a novel logistic regression model. J Viral Hepat.
16:464–470. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yu JW, Sun LJ, Zhao YH and Li SC:
Prediction value of model for end-stage liver disease scoring
system on prognosis in patients with acute-on-chronic hepatitis B
liver failure after plasma exchange and lamivudine treatment. J
Gastroenterol Hepatol. 23:1242–1249. 2008. View Article : Google Scholar
|
|
8
|
Lee WC, Chou HS, Wu TJ, Lee CS, Lee CF and
Chan KM: Indicators and outcome of liver transplantation in acute
liver decompensation after flares of hepatitis B. J Viral Hepat.
18:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng MH, Shi KQ, Fan YC, Li H, Ye C, Chen
QQ and Chen YP: A model to determine 3-month mortality risk in
patients with acute-on-chronic hepatitis B liver failure. Clin
Gastroenterol Hepatol. 9:351–356. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai CJ, Chen HA, Lu MQ and Chen GH: Model
for end-stage liver disease-sodium predicts prognosis in patients
with chronic severe hepatitis B. Chin Med J (Engl). 121:2065–2069.
2008.
|
|
11
|
Lee WM, Squires RH Jr, Nyberg SL, Doo E
and Hoofnagle JH: Acute liver failure: summary of a workshop.
Hepatology. 47:1401–1415. 2008.PubMed/NCBI
|
|
12
|
Novelli G, Rossi M, Ferretti G, Pugliese
F, Travaglia D, Guidi S, Novelli S, Lai Q, Morabito V and Berloco
PB: Predictive parameters after molecular absorbent recirculating
system treatment integrated with model for end stage liver disease
model in patients with acute-on-chronic liver failure. Transplant
Proc. 42:1182–1187. 2010. View Article : Google Scholar
|
|
13
|
Garg H, Sarin SK, Kumar M, Garg V, Sharma
BC and Kumar A: Tenofovir improves the outcome in patients with
spontaneous reactivation of hepatitis B presenting as
acute-on-chronic liver failure. Hepatology. 53:774–780. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Q, Liu Z, Wang T, Wang Q, Shi X and
Dao W: Characteristics of acute and sub-acute liver failure in
China: nomination, classification and interval. J Gastroenterol
Hepatol. 22:2101–2106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu XY, Hu JH, Wang HF and Chen JM:
Etiological analysis of 1977 patients with acute liver failure,
subacute liver failure and acute-on-chronic liver failure. Zhonghua
Gan Zang Bing Za Zhi. 16:772–775. 2008.(In Chinese).
|
|
16
|
Kamath PS, Wiesner RH, Malinchoc M,
Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER and Kim
WR: A model to predict survival in patients with end-stage liver
disease. Hepatology. 33:464–470. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sharma P, Schaubel DE, Sima CS, Merion RM
and Lok AS: Re-weighting the model for end-stage liver disease
score components. Gastroenterology. 135:1575–1581. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luca A, Angermayr B, Bertolini G, Koenig
F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B and Bosch
J: An integrated MELD model including serum sodium and age improves
the prediction of early mortality in patients with cirrhosis. Liver
Transpl. 13:1174–1180. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heuman DM, Mihas AA, Habib A, Gilles HS,
Stravitz RT, Sanyal AJ and Fisher RA: MELD-XI: a rational approach
to ‘sickest first’ liver transplantation in cirrhotic patients
requiring anticoagulant therapy. Liver Transpl. 13:30–37.
2007.PubMed/NCBI
|
|
20
|
Kim WR, Biggins SW, Kremers WK, Wiesner
RH, Kamath PS, Benson JT, Edwards E and Therneau TM: Hyponatremia
and mortality among patients on the liver-transplant waiting list.
N Engl J Med. 359:1018–1026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neuberger J, Gimson A, Davies M, Akyol M,
O’Grady J, Burroughs A and Hudson M; Liver Advisory Group. UK Blood
and Transplant: Selection of patients for liver transplantation and
allocation of donated livers in the UK. Gut. 57:252–257. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bewick V, Cheek L and Ball J: Statistics
review 13: receiver operating characteristic curves. Crit Care.
8:508–512. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
DeLong ER, DeLong DM and Clarke-Pearson
DL: Comparing the areas under two or more correlated receiver
operating characteristic curves: a nonparametric approach.
Biometrics. 44:837–845. 1988. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Biggins SW, Rodriguez HJ, Bacchetti P,
Bass NM, Roberts JP and Terrault NA: Serum sodium predicts
mortality in patients listed for liver transplantation. Hepatology.
41:32–39. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huo SC, Huo TI, Lin HC, Chi CW, Lee PC,
Tseng FW and Lee SD: Is the corrected-creatinine model for
end-stage liver disease a feasible strategy to adjust gender
difference in organ allocation for liver transplantation?
Transplantation. 84:1406–1412. 2007. View Article : Google Scholar
|
|
26
|
Merion RM, Wolfe RA, Dykstra DM, Leichtman
AB, Gillespie B and Held PJ: Longitudinal assessment of mortality
risk among candidates for liver transplantation. Liver Transpl.
9:12–18. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee
PC, Chang FY and Lee SD: Evaluation of the increase in model for
end-stage liver disease (DeltaMELD) score over time as a prognostic
predictor in patients with advanced cirrhosis: risk factor analysis
and comparison with initial MELD and Child-Turcotte-Pugh score. J
Hepatol. 42:826–832. 2005. View Article : Google Scholar
|
|
28
|
Liver Failure and Artificial Liver Group,
Chinese Society of Infectious Diseases, Chinese Medical
Association; Severe Liver Diseases and Artificial Liver Group,
Chinese Society of Hepatology, Chinese Medical Association.
Diagnostic and treatment guidelines for liver failure. Zhonghua Gan
Zang Bing Za Zhi. 14:643–646. 2006.(In Chinese).
|
|
29
|
Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH,
Chan HY, Sung JJ and Chan HL: Entecavir treatment in patients with
severe acute exacerbation of chronic hepatitis B. J Hepatol.
54:236–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lange CM, Bojunga J, Hofmann WP, Wunder K,
Mihm U, Zeuzem S and Sarrazin C: Severe lactic acidosis during
treatment of chronic hepatitis B with entecavir in patients with
impaired liver function. Hepatology. 50:2001–2006. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Christensen E: Prognostic models including
the Child-Pugh, MELD and Mayo risk scores–where are we and where
should we go? J Hepatol. 41:344–350. 2004.PubMed/NCBI
|
